Tuberculosis remains a major health problem throughout the world causing large number of deaths. Effective disease control and eradication programs require the identification of major antigens recognized by the protective responses against M. tuberculosis.
The work reported within this article demonstrates how Ag85A and ESAT-6 are antigens able to differentiate pulmonary, extra-pulmonary and tuberculosis patients undergoing chemotherapy from healthy individuals by IFN- γ production and pulmonary and under treatment patients from extra-pulmonary TB by TNF-α. Therefore, not only IFN-γ production but also TNF-α to Ag85A and ESAT-6 could be used as biomarkers for the clinical status of TB patients while IL-10 could be useful monitoring TB successful treatment.
The article is published online within the journal, Clinical and Developmental Immunology and is free to access.